ECOG-ACRIN E3805/CHAARTED investigators (Eur Urol Oncol 2025, 2025-02: An exploratory analysis of patient-reported quality of life in CHAARTED found that baseline symptom burden modified the survival benefit of docetaxel: the most symptomatic men appeared to benefit, the least symptomatic did not.
The most symptomatic patients appeared to benefit from docetaxel, while the least symptomatic patients did not. QOL may enhance decision-making when choosing treatment for metastatic hormone-sensitive prostate cancer.
Abstract
ECOG-ACRIN E3805/CHAARTED investigators (Eur Urol Oncol 2025, 2025-02: An exploratory analysis of patient-reported quality of life in CHAARTED found that baseline symptom burden modified the survival benefit of docetaxel: the most symptomatic men appeared to benefit, the least symptomatic did not. Funder: NCI/ECOG-ACRIN (same trial as CHH-09); Sanofi supplied docetaxel in the parent trial. Conflicts: not captured in the PMC author-manuscript version. Maker: Sanofi. Comparator: ADT alone. Confidence MEDIUM because only the structured abstract of the PMC author manuscript was retrievable – the full PRO tables (FACT-P, worst pain, fatigue) were not; no web.archive.org snapshot exists for the PMC URL.
